

**IN THE CLAIMS:**

1-20.(Cancelled)

21.(Previously presented)     A pharmaceutical composition comprising the antibody of any one of Claims 29-33.

22-28.(Cancelled)

29.(Previously presented)     An antibody directed against an isolated IL-16 antagonist peptide consisting of CLLS (SEQ ID NO:2).

30.(Previously presented)     An antibody directed against an isolated IL-16 antagonist peptide consisting of any one of WQCLLS (SEQ ID NO:4), WQALLS (SEQ ID NO:5), VVQVVA (SEQ ID NO:9) or VKQVVA (SEQ ID NO:11).

31.(Previously presented)     An antibody directed against an isolated IL-16 antagonist peptide consisting of GMWQCLLS (SEQ ID NO:13).

32.(Previously presented)     An antibody directed against an isolated IL-16 antagonist peptide consisting of GMWQCLLSDSGQVLLE (SEQ ID NO:12).

33.(Previously presented)     An antibody directed against an isolated IL-16 antagonist peptide consisting of TGLWQCLLSEGD (SEQ ID NO:14).

34.(Previously presented)     An antibody directed against an isolated IL-16 antagonist peptide consisting of VSEEQKVQVVA (SEQ ID NO:15).

35.(Cancelled)